Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin

被引：11

作者：

Desar, Ingrid M. E. ^{[1
]}

Constantinidou, Anastasia ^{[2
,3
]}

Kaal, Suzanne E. J. ^{[1
]}

Jones, Robin L. ^{[2
,3
]}

van der Graaf, Winette T. A. ^{[1
,2
,3
]}

机构：

[1] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands

[2] Inst Canc Res, 15 Cotswold Rd, London SM2 5NG, England

[3] Royal Marsden NHS Fdn Trust, London, England

来源：

CANCER MANAGEMENT AND RESEARCH | 2016年 / 8卷

关键词：

soft-tissue sarcoma; trabectedin; chemotherapy; RANDOMIZED PHASE-II; GEMCITABINE PLUS DOCETAXEL; FIXED-DOSE-RATE; METASTATIC UTERINE LEIOMYOSARCOMA; DOXORUBICIN-BASED CHEMOTHERAPY; BONE-SARCOMA; 1ST-LINE TREATMENT; EUROPEAN-ORGANIZATION; ADULT PATIENTS; OPEN-LABEL;

D O I：

10.2147/CMAR.S86746

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy.

引用

页码：95 / 104

页数：10

共 50 条

[1] Trabectedin expands treatment options for some forms of advanced soft tissue sarcoma
Abraham, Jame
[J]. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2016, 14 (05): : 189 - 191
[2] Trabectedin for treatment of advanced soft-tissue sarcoma: a 18 months regional evaluation
Haupais, H.
Caussin, M.
Basuyau, F.
Guillemet, C.
Doucet, J.
Remy, E.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2012, 34 (01) : 222 - 222
[3] Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal
Rachid Rafia
Emma Simpson
Matt Stevenson
Diana Papaioannou
[J]. PharmacoEconomics, 2013, 31 : 471 - 478
[4] Trabectedin for the management of soft-tissue sarcoma
Boudou, Laurence
Baconnier, Mathieu
Blay, Jean-Yves
Lombard-Bohas, Catherine
Cassier, Philippe A.
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 727 - 737
[5] Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal
Rafia, Rachid
Simpson, Emma
Stevenson, Matt
Papaioannou, Diana
[J]. PHARMACOECONOMICS, 2013, 31 (06) : 471 - 478
[6] Trabectedin for the treatment of advanced metastatic soft tissue sarcoma
Simpson, E. L.
Rafia, R.
Stevenson, M. D.
Papaioannou, D.
[J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 63 - 67
[7] Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma
Doherty, Gary J.
Davidson, Dochka
Wong, Han H.
Hatcher, Helen M.
[J]. ANTI-CANCER DRUGS, 2019, 30 (01) : 110 - 115
[8] TREATMENT OF ADVANCED SOFT-TISSUE SARCOMA
ROSENBAUM, C
SCHOENFELD, D
[J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 287 - 287
[9] Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma
Cioffi, Angela
Italiano, Antoine
[J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (01) : 113 - 122
[10] ADJUVANT CHEMOTHERAPY FOR SOFT-TISSUE SARCOMA - A CRITICAL-APPRAISAL
ELIAS, AD
ANTMAN, KH
[J]. SEMINARS IN SURGICAL ONCOLOGY, 1988, 4 (01): : 59 - 65

← 1 2 3 4 5 →